Kernal Bio

Kernal Bio is a venture-backed biotech company developing mRNA 2.0 immunotherapies. Kernal Bio mines massive translatome data to discover cell-specific sequence features and to design mRNAs that are selectively translated in cancer cells. These mRNAs are formulated with proprietary LNPs for extrahepatic delivery. KR-335, the company's lead program showed high efficacy and safety in preclinical tumor models that are resistant to checkpoint inhibitors. With roots at MIT, Harvard and Biopharma, Kernal Bio’s management team has deep expertise in mRNA therapeutics space. As a leader in next generation mRNA therapeutics space, Kernal Bio has a 24 patent-wide IP portfolio. The company is based in Cambridge, MA and backed by Hummingbird, Amgen Ventures, and HBM.